Vancomycin hydrochloride

An antibiotic used to treat a number of bacterial infections that acts by inhibiting proper cell wall synthesis.Bacterial Infection Approved (In Vitro) :Vancomycin is a large glycopeptide compound with a molecular weight of 1450 Da. Vancomycin is a unique glycopeptide structurally unrelated to any currently available antibiotic. It also has a unique mode of action inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin is active against a large number of species of Gram-positive bacteria, such as Staphylococcus aureus, Staph. epidermidis, Str. agalactiae, Str. bovis, Str. mutans, viridans streptococci, enterococci. (In Vivo) :Vancomycin is administered intravenously, with a standard infusion time of at least 1 h, to minimize infusion-related adverse effects. Subjects with normal creatinine clearance, vancomycin has an α-distribution phase of 30 min to 1 h and a β-elimination half-life of 6-12 h. The volume of distribution is 0.4–1 L/kg. The binding of vancomycin to protein ranges from 10% to 50%. Factors that affect the overall activity of vancomycin include its tissue distribution, inoculum size, and protein-binding effects. Vancomycin treatment of infected mice is associated with improved clinical, diarrhea, and histopathology scores and survival during treatment.

1404-93-9

Lyphocin

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 24 mg/mL

C[C@H]1[C@H] ([C@@] (C[C@@H] (O1) O[C@@H]2[C@H] ([C@@H] ([C@H] (O[C@H]2OC3=C4C=C5C=C3OC6=C (C=C (C=C6) [C@H] ([C@H] (C (=O) N[C@H] (C (=O) N[C@H]5C (=O) N[C@@H]7C8=CC (=C (C=C8) O) C9=C (C=C (C=C9[C@H] (NC (=O) [C@H] ([C@@H] (C1=CC (=C (O4) C=C1) Cl) O) NC7=O) C (=O) O) O) O) CC (=O) N) NC (=O) [C@@H] (CC (C) C) NC) O) Cl) CO) O) O) (C) N) O.Cl

C66H76Cl3N9O24

1485.715

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.